Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, Cui ZL, Bowman L. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. J Med Econ. 2020 Mar;23(3):213-20. doi: 10.1080/13696998.2019.1678479
Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301
Nazareth T, Purser M, Bhaila R, Philbin M, Mladsi D. The economic burden of moderate-to-severe multiple sclerosis relapse in the United States: findings from a systematic literature review. Poster presented at the 69th AAN Annual Meeting; April 2017. Boston, MA. [abstract] Neurology. 2017 Apr 18; 88(16 Suppl).
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.